The quarter came in below the standing benchmark. Sanara’s own prior Q2 revenue guide was $28.5 million–$29.5 million, while published consensus was approximately $28.95 million; actual revenue was $28.14 million, a shortfall versus both the midpoint and consensus. Published EPS consensus was approximately negative $0.03, versus reported continuing-operations EPS of negative $0.05.
| Metric | Q2 2026 | Q2 2025 / expectation | Read |
|---|---|---|---|
| Net revenue | $28.1M | $25.8M prior year; $28.5M–$29.5M company guide; ~$28.95M consensus | 9% year-over-year growth, but below benchmarks (Financial Highlights; Revenue by product) |
| Gross margin | 93% | 92% prior year | Favorable mix and pricing (Financial Highlights; Income Statement) |
| Operating income | $1.8M | $2.5M prior year | Lower despite higher revenue (Income Statement) |
| Continuing-operations EPS | $(0.05) | $0.05 prior year; approximately $(0.03) consensus | Missed published expectation (Income Statement) |
| Adjusted EBITDA | $5.0M | $4.7M prior year | Modest improvement, but below the pace of revenue growth (Adjusted EBITDA reconciliation) |
| Operating cash flow | $(0.4)M first six months | $0.7M provided prior year | Cash generation deteriorated (Cash Flow statement) |
| Cash / long-term debt | $15.4M / $46.5M | $16.6M / $46.0M at December 31, 2025 | Less cash and slightly more debt (Balance Sheet) |
Revenue growth remains real, but the quality of the quarter weakened. Soft-tissue repair revenue rose 11% to $25.2 million, more than offsetting an 8% decline in bone-fusion revenue to $2.9 million. Gross margin improved to 93%, yet operating expenses climbed 14%—faster than revenue—because of higher sales spending, compensation, and roughly $1.1 million of legal and advisory costs tied to strategic initiatives. That pushed operating income down 28% to $1.8 million (Revenue by product; Income Statement; Management discussion).
Adjusted EBITDA improved, but mostly preserves rather than expands operating leverage. Adjusted EBITDA increased only $0.3 million to $5.0 million despite $2.3 million of additional revenue. The result was helped by gross-margin expansion but restrained by higher SG&A; the company also excluded $1.1 million of acquisition and transaction-related costs from the measure (Adjusted EBITDA reconciliation). GAAP continuing operations consequently swung to a $0.4 million loss, with higher cash interest and equity-method investment losses adding pressure (Income Statement).
The balance-sheet signal is less comfortable than the headline growth rate. Sanara used $0.4 million of operating cash in the first half versus generating $0.7 million a year earlier, while cash fell to $15.4 million and long-term debt rose to $46.5 million. Management attributes the cash deterioration to commission timing and higher cash interest after the shift away from paid-in-kind interest; regardless, the filing shows that stronger EBITDA has not yet translated into stronger cash generation (Cash Flow statement; Balance Sheet).
The MIMEDX transaction is important context, but not new information in this release. The proposed acquisition was already announced after quarter-end and remains subject to closing conditions, so its mention does not materially change the quarter’s operating read. On the numbers, the filing is a mild miss: growth and margins are healthy, but revenue and EPS fell short of benchmarks, while expense growth and cash conversion moved in the wrong direction (Management commentary; Forward-looking statements).
Read the original 8-K on SEC EDGAR ↗